Stabl-Im Clinical Development Update
Filed with ASX · · 3 pages · English
Summary by 6ix AI
TrivarX Limited has released an update on the Stabl-Im clinical development program, detailing advancements in key clinical and pre-clinical activities. The company has completed the design requirements for a clinical feasibility study and is progressing with pre-clinical studies and operational preparations. TrivarX is also in the process of selecting clinical sites and principal investigators to support the upcoming study. Additionally, discussions are ongoing with a vendor for specialized deuterium analysis necessary for the clinical study.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from TrivarX
- June 2026 Quarterly Activities Report and Appendix 4C
- Stabl-Im clinical trial supply milestone achieved
- CRO Engaged to Advance Stabl-Im Phase 1 Trial
- March 2026 Quarterly Activities Report and Appendix 4C
- Dr Danielle Meyrick appointed as CEO
Later from TrivarX
- Syntro Health Appointed to Support Stabl-Im Clinical Program
- September 2026 Quarterly Activities Report and Appendix 4C
Follow TrivarX into a list and get an email when it puts out news.
Follow TrivarX